<DOC>
	<DOCNO>NCT00513357</DOCNO>
	<brief_summary>The goal clinical research study evaluate effectiveness melatonin management poor appetite weight loss advance cancer patient . The effectiveness melatonin weight gain , keeping/gaining lean muscle mass , improve appetite , side effect also evaluate .</brief_summary>
	<brief_title>Melatonin Versus Placebo Effect Appetite Advanced Cancer Patients</brief_title>
	<detailed_description>Melatonin hormone make part brain call pineal gland may help let body know time go sleep time wake . The researcher feel melatonin might help improve appetite , improve overall sense well-being , maintain current weight . If find eligible take part study , see nutritionist first ( baseline ) visit . The nutritionist measure amount calorie consume . You ask report food drink 3-day period . If unable remember eat drunk last 3 day , ask nutritionist list food drink within last 24 hour . Your arm muscle diameter skin fold shoulder blade measure arm n't normally use write . This determine body fat , lean mass water content body . Your rest energy expenditure measure . You ask wear breathe mask blow tube . This allow breath analyze , measure many calorie body use rest . Blood ( 1-2 tablespoon ) draw test make sure treatable cause weight loss . This blood test may need repeat blood test last 3 month . If find eligible take part study , randomly assign ( toss coin ) one 2 group . Participants Group 1 take melatonin daily bedtime 4 week . Patients Group 2 take placebo daily bedtime 4 week . A placebo substance look like study drug active ingredient . You equal chance ( 50/50 ) place either group . Neither medical staff researcher study know receive study drug placebo . On Week 2 , return clinic repeat test do baseline visit . If unable return M. D. Anderson complete evaluation Day 14 ( Â± 2 day ) , research nurse contact telephone ask side effect experience . At Week 4 , return clinic test do baseline repeat . At end 4 week , study patient group give opportunity take melatonin go sleep night additional 4 week . If choose continue melatonin additional 4 week , take study blood draw end study test include albumin , C-reactive protein ( CRP ) , thyroid stimulate hormone ( TSH ) , vitamin B-12 , cortisol . These test require 1-2 tablespoon blood drawn . If choose continue melatonin additional 4 week , ask return outpatient clinic Week 6 repeat test do baseline . Your end study test do end 8 week . You continue visit study doctor outpatient clinic long feel necessary . At visit , height weight record ask food drink . This investigational study . Melatonin currently approve FDA except treat blind people light perception sleep disorders-and consider food/nutritional supplement . Up 126 patient enrol MD Anderson Duke University Medical Center Durham , North Carolina .</detailed_description>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>1 . Patients solid gastrointestinal tumor lung cancer patient refer palliative care 5 % involuntary weight loss within last 6 month anorexia ( &gt; 3 visual analog scale ESAS ) 2 . Greater equal 18 year age 3 . Karnofsky score 40 high 4 . Patient ability maintain oral food intake study period 5 . If patient persistent anorexia/cachexia currently take Megace , corticosteroid , nonsteroidal antiinflammatories ( NSAID 's ) , thalidomide , medication least 2 week prior study inclusion 6 . Ability sign inform consent understand study procedures 7 . Patient continue medication include complementary therapy antineoplastic therapy onstudy melatonin stable dose least 2 week 8 . Negative pregnancy test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 9 . Patients take Megace past history elevate risk DVT , adrenal insufficiency , impotence , hyperglycemia , CHF , menorrhagia , etc . 10 . Patients persistent anorexia/cachexia treatment Megace fail 1 . Patients dementia delirium entry study determine palliative care specialist use DSMIVcriteria 2 . Patients currently take melatonin 3 . Inability take oral food study period 4 . Unstable secondary cachexia cause nausea , diarrhea , taste abnormality , mucositis , constipation , dysphagia , clinical depression prior study inclusion . These symptom resolve stable &gt; /= 2 week time inclusion study determine Palliative Care Specialist . 5 . Inability sign inform consent understand study procedures 6 . Karnofsky score &lt; 40 7 . Patients &lt; 18 year age 8 . Patients &lt; /= 5 % involuntary weight loss within last 6 month anorexia &lt; 3 ESAS 9 . Patients complementary therapy contain melatonin medication &lt; 2 week stable dose 10 . Patients cortisol level &lt; /= 4.3 mg/dL baseline exclude , unless replacement corticosteroid . 11 . Patients TSH &lt; /= 0.50 &gt; /= 10 mcL/mL baseline exclude 12 . Pregnant female female lactating/nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Gastrointestinal Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Anorexia</keyword>
	<keyword>Weight Loss</keyword>
</DOC>